Evolution of thyroid cancer biomarkers: from laboratory test to patients' clinical management.
| Autor: | Garo ML; Mathsly Research, Roma, Italy., Campennì A; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy., Petranovic-Ovcaricek P; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia., D'Aurizio F; Department of Laboratory Medicine, Institute of Clinical Pathology, Santa Maria della Misericordia University Hospital, Udine, Italy., Giovanella L; Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.; Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2022 Nov 11; Vol. 61 (5), pp. 935-945. Date of Electronic Publication: 2022 Nov 11 (Print Publication: 2023). |
| DOI: | 10.1515/cclm-2022-1087 |
| Abstrakt: | Over the past three decades, laboratory medicine has significantly evolved thanks to technological advances made possible by new materials and evidence. Clinicians' ongoing requests for powerful, rapid, and minimally invasive tests has led manufacturers to develop rapid, accurate, and sensitive tests that can increase diagnostic accuracy and improve follow-up, bringing laboratory medicine ever closer to personalized medicine. The aim of this study was to critically review the main problems of the current Tg and CT biomarkers for the diagnosis/monitoring of DTC and MTC, respectively, and to identify the advantages and challenges of using the new laboratory biomarkers in the clinical management of patients with differentiated and medullary thyroid cancer. Insufficient harmonization of Tg and CT assays and lack of interchangeability of laboratory results and cutoff values pose challenges for comparability and standardization of procedures and methods. New diagnostic and monitoring approaches such as PCT or the Tg doubling time have proven to be effective. Close collaboration between clinicians and laboratory specialists remains essential to translate the advantages and limitations of current assays into appropriate clinical interpretation criteria. Over the years, the journal Clinical Chemistry and Laboratory Medicine ( CCLM ) has taken many steps to develop advanced research and technology in the diagnosis and monitoring of tumor cancer and to help clinicians translate it into clinical practice. (© 2022 Walter de Gruyter GmbH, Berlin/Boston.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|